Tricida Announces Updates on Veverimer Development Program, Regulatory Status and New Patent Extending Protection through 2038

NEXT STORY
Monthly information on share capital and company voting rights
PREV STORY
HTG Announces an Early Access Program for its Prototype Whole Transcriptome Panel
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

G1 Therapeutics to Present at Raymond James Life Sciences and MedTech Conference

author_avatar
NASDAQ Market News

Shire plc : U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation

 U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation NDA ...

author_avatar
NASDAQ Market News

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

author_avatar
NASDAQ Market News